Half-matched stem cell transplant in older adults with acute leukemia or MDS
Follows older adults with acute leukemia or myelodysplastic syndromes after transplant.
Plain-language title generated from the registry record
Registry title: Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 55 to under 70 with acute leukemia or MDS who can have a stem cell transplant from a half-matched family donor.
- Age
- 55 years or older and under 70 years
- Sex
- All sexes can join.
- Disease stage
- Acute leukemia or myelodysplastic syndrome (MDS), with or without an HCT-CI score of 3 or more.
- Earlier treatment
- Not stated. People must be able to have a stem cell transplant from a donor.
- Biomarker or test result
- No fully tissue-compatible (HLA) donor available, but a haploidentical (half-compatible) donor is available.
Main reasons for not taking part
- Severe infection
- Pregnant or breastfeeding women
- Not able to have a stem cell transplant
- Took part in another clinical trial within 1 month
- Cannot understand or refuses the consent form
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 70 years old?
Source: NCT05902416, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Yuqian SunTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT05902416
- Record updated
- 19 September 2024
- Original description
This study is an open, prospective, single-center, single-arm study expanded based on the study of NCT03412409.The primary objective of this study is to evaluate the transplantation efficacy of the RIC conditioning regimen in elderly patients receiving the transplantation of haploidentical hematopoietic stem cells. Elderly patients are defined as ≥55 years of age; High comorbidity is defined as an HCT-CI score ≥3.Primary endpoint is 1-year LFS. Secondary endpoints are 1-year OS and 1-year TRM, Other indicators to be assessed in this study include acute GVHD, chronic GVHD, CMV activation, EBV activation, engraftment.Read full original descriptionShow less
Clinical Registration Study of Haploidentical Stem Cell Transplantation for Elderly Patients With Acute Leukemia or Myelodysplastic Syndrome
This study is an open, prospective, single-center, single-arm study expanded based on the study of NCT03412409.The primary objective of this study is to evaluate the transplantation efficacy of the RIC conditioning regimen in elderly patients receiving the transplantation of haploidentical hematopoietic stem cells. Elderly patients are defined as ≥55 years of age; High comorbidity is defined as an HCT-CI score ≥3.Primary endpoint is 1-year LFS. Secondary endpoints are 1-year OS and 1-year TRM, Other indicators to be assessed in this study include acute GVHD, chronic GVHD, CMV activation, EBV activation, engraftment.
Inclusion: Patients ≥55 years of age and <70 years of age, with acute leukemia or MDS (with or without HCT-CI≥3); Patients eligible for the transplantation of allogeneic hematopoietic stem cells; Patients unavailable with HLA matched donors but available with haploidentical donors; Voluntary participation in this study and signing the informed consent form.
Exclusion: Patients who are not eligible for hematopoietic stem cell transplantation; Patients with the severe infections; Pregnant or lactating women or female and male subjects of childbearing age and their spouses who are unable to secure effective contraception during the dosing period and within 90 days after the end of the dosing period; Patients who are enrolled in other clinical trials within 1 month; Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study; Patients unable to properly understand or refusing to accept the informed consent form.